IL291224A - New molecules for diagnosis - Google Patents

New molecules for diagnosis

Info

Publication number
IL291224A
IL291224A IL291224A IL29122422A IL291224A IL 291224 A IL291224 A IL 291224A IL 291224 A IL291224 A IL 291224A IL 29122422 A IL29122422 A IL 29122422A IL 291224 A IL291224 A IL 291224A
Authority
IL
Israel
Prior art keywords
diagnosis
novel molecules
molecules
novel
Prior art date
Application number
IL291224A
Other languages
English (en)
Hebrew (he)
Inventor
Oskar Adolfsson
Katarzyna Ewa Piorkowska
Original Assignee
Ac Immune Sa
Oskar Adolfsson
Katarzyna Ewa Piorkowska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa, Oskar Adolfsson, Katarzyna Ewa Piorkowska filed Critical Ac Immune Sa
Publication of IL291224A publication Critical patent/IL291224A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
IL291224A 2019-09-10 2022-03-09 New molecules for diagnosis IL291224A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196512 2019-09-10
EP20184340 2020-07-06
PCT/EP2020/075420 WO2021048324A1 (en) 2019-09-10 2020-09-10 Novel molecules for diagnosis

Publications (1)

Publication Number Publication Date
IL291224A true IL291224A (en) 2022-05-01

Family

ID=72356005

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291224A IL291224A (en) 2019-09-10 2022-03-09 New molecules for diagnosis

Country Status (10)

Country Link
US (1) US20230034474A1 (https=)
EP (1) EP4028127A1 (https=)
JP (2) JP2022547993A (https=)
KR (1) KR20220087439A (https=)
CN (1) CN114650866B (https=)
AU (1) AU2020347483A1 (https=)
CA (1) CA3149837A1 (https=)
IL (1) IL291224A (https=)
MX (1) MX2022002873A (https=)
WO (1) WO2021048324A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121002061A (zh) * 2023-01-12 2025-11-21 弗吉尼亚大学专利基金委员会 抗cith3抗体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN117567635B (zh) * 2024-01-16 2024-05-14 恺佧生物科技(上海)有限公司 抗Cas9酶的抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
US20100074901A1 (en) * 2007-10-15 2010-03-25 Marc Hubert Mercken Human anti-amyloid antibodies, compositions, methods and uses
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
JP5599454B2 (ja) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP6027011B2 (ja) * 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物

Also Published As

Publication number Publication date
KR20220087439A (ko) 2022-06-24
WO2021048324A1 (en) 2021-03-18
JP2025178565A (ja) 2025-12-08
CN114650866B (zh) 2025-08-01
EP4028127A1 (en) 2022-07-20
MX2022002873A (es) 2022-03-25
JP2022547993A (ja) 2022-11-16
CN114650866A (zh) 2022-06-21
WO2021048324A9 (en) 2022-05-05
CA3149837A1 (en) 2021-03-18
US20230034474A1 (en) 2023-02-02
AU2020347483A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
IL279219A (en) New compounds for diagnosis
IL290104A (en) diagnostic system
GB202018087D0 (en) No details
SG11202009515RA (en) Vista antigen-binding molecules
GB202017837D0 (en) No details
GB202013426D0 (en) No Details
CA208605S (en) Instrument
GB202009212D0 (en) No details
GB201814562D0 (en) Vista antigen-binding molecules
IL285162A (en) survival-directed chimeric molecules (surtac)
IL292119A (en) conjugated molecules
IL289266B1 (en) New molecules
IL291224A (en) New molecules for diagnosis
CA191673S (en) Diagnostic cartridge
GB201916046D0 (en) Diagnostic method
SI3834594T1 (sl) Kolo s strgalom za sejalnik
IL293228B2 (en) Diagnostic techniques based on alignment of speech samples
GB202015405D0 (en) No details
GB201908591D0 (en) Methods for cancer diagnosis
GB202014354D0 (en) No details
IL282230A (en) chimeric molecules
GB201904861D0 (en) Diagnosis
EP3268577A4 (en) Steam quality diagnostic meter
GB202006205D0 (en) No details
HUE064848T2 (hu) Diagnosztikai berendezés